Label: Information for the User
Kaletra 100 mg/25 mg Film-Coated Tablets
lopinavir/ritonavir
Read this label carefully before taking this medicine because it contains important information for you or your child.
1. What is Kaletra and for what it is used
2. What you need to know before you or your child take Kaletra
3. How to take Kaletra
4. Possible adverse effects
5. Storage of Kaletra
6. Contents of the package and additional information
Do not take Kaletra with any of the following medications:
For more information on other medications that require special precautions, see the list of medications included below in “Other medications and Kaletra”.
If you are currently taking any of these medications, consult your doctor to see if you need to change your treatment for other conditions or your antiretroviral treatment.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Kaletra.
Important information
Inform your doctor if you or your child have or have had
Inform your doctor if you or your child experience
Other medications and Kaletra
Inform your doctor or pharmacist if you or your child are taking, have taken recently, or may need to take any other medication.
For more information on other medications that should not be taken while taking Kaletra, see the list of medications included above in “Do not take Kaletra with any of the following medications”.
Inform your doctor or pharmacist if you or your child are taking, have taken recently, or may need to take other medications, including those obtained without a prescription.
Medications for erectile dysfunction (e.g. avanafil, vardenafil, sildenafil, and tadalafil)
Contraceptives
Pregnancy and breastfeeding
Driving and operating machinery
No specific studies have been conducted on the effects of Kaletra on the ability to drive and operate machinery. Do not drive or operate machinery if you experience any adverse effects (e.g. nausea) that may affect your ability to do so safely. Consult your doctor.
It is essential to swallow Kaletra tablets whole and not to chew, break, or crush them.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How and when to take Kaletra
Use in adults
Use in children 2 years of age or older
Kaletra is also available in 200 mg/50 mg film-coated tablets. Kaletra oral solution is available for patients who cannot take tablets.
If you or your child take more Kaletra than you should
If you or your child forget to take Kaletra
If you are taking Kaletra twice a day
If you are taking Kaletra once a day
If you or your child stop taking Kaletra
During HIV treatment, there may be an increase in weight and blood glucose and lipid levels. This may be partly related to recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medicines themselves. Your doctor will monitor these changes.
The following side effects have been reported by patients who took this medicine.You should inform your doctor quickly about these or any other symptoms. See your doctor if they persist or worsen.
Very common:may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Rare:may affect up to 1 in 1,000people
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this prospectus, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus.You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
How should I dispose of unused Kaletra?
Unused medications should not be flushed down the drain or thrown away.
Ask your pharmacist how to dispose of the packaging and unused medications. This will help protect the environment.
The active ingredients are lopinavir and ritonavir.
Each Kaletra tablet contains 100 mg of lopinavir and 25 mg of ritonavir.
The other components are:
Tablet
Colloidal anhydrous silica, copovidone, sodium stearate fumarate, sorbitan laurate.
Capsule coating
Polyvinyl alcohol, talc, titanium dioxide, macrogol 3350 (polyethylene glycol 3350), yellow iron oxide E-172.
Appearance of the product and contents of the pack
Kaletra coated tablets are pale yellow in color with a raised impression of (Abbott logo) and “KC”.
Kaletra 100 mg/25 mg coated tablets with a film coating are presented in plastic bottles containing 60 tablets.
Marketing authorization holder:
AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Responsible for manufacturing:
AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
For more information about this medicine, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien AbbVie SA Tel: +32 10 477811 | Lietuva AbbVie UAB Tel: +370 5 205 3023 | |
???????? ???? ???? ???.: +359 2 90 30 430 | Luxembourg/Luxemburg AbbVie SA Belgique/Belgien Tél/Tel: +32 10 477811 | |
Ceská republika AbbVie s.r.o. Tel: +420 233 098 111 | Magyarország AbbVie Kft. Tel.: +36 1 455 8600 | |
Danmark AbbVie A/S Tlf: +45 72 30-20-28 | Malta V.J.Salomone Pharma Limited Tel: +356 22983201 | |
Deutschland AbbVie DeutschlandGmbH & Co. KG Tel: 00800 222843 33 (free of charge) Tel: +49 (0) 611/1720-0 | Nederland AbbVie B.V. Tel: +31 (0)88 322 2843 | |
Eesti AbbVie Biopharmaceuticals GmbH Eesti filiaal Tel: +372 623 1011 | Norge AbbVie AS Tlf: +47 67 81 80 00 | |
Ελλ?δα AbbVieΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Τηλ: +30214 4165 555 | Österreich AbbVie GmbH Tel: +43 1 20589-0 | |
España AbbVie Spain, S.L.U. Tel: +34 9 1 384 09 10 | Polska AbbVie Polska Sp. z o.o. Tel.: +48 22372 78 00 | |
France AbbVie Tél: +33 (0)1 45 60 13 00 | Portugal AbbVie, Lda. Tel: +351 (0)21 1908400 |
Hrvatska AbbVie d.o.o. Tel: +385 (0)15625 501 | România AbbVie S.R.L. Tel: +40 21 529 30 35 | |
Ireland AbbVie Limited Tel: +353 (0)1 4287900 | Slovenija AbbVie Biofarmacevtska družba d.o.o. Tel: +386 (1)32 08 060 | |
Ísland Vistor hf. Tel: +354 535 7000 | Slovenská republika AbbVie s.r.o. Tel: +421 2 5050 0777 | |
Italia AbbVie S.r.l. Tel: +39 06 928921 | Suomi/Finland AbbVie Oy Puh/Tel: +358 (0)10 2411 200 | |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: +357 22 34 74 40 | Sverige AbbVie AB Tel: +46(0)8 684 44 600 | |
Latvija AbbVie SIA Tel: +371 67605000 | United Kingdom AbbVie Ltd Tel: +44 (0)1628 561090 |
Last review date of this leaflet:
The detailed information about this medicine is available on the website of the European Medicines Agency http://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.